Trends from the Trenches

It’s no secret that the industry is drowning in data. That’s why data management strategies are needed now more than ever to speed up discoveries and bring new solutions to the market. In this episode of Trends from the Trenches, host Stan Gloss discusses data management strategies with Becky Upton, Ph. D., President of Pistoia Alliance. Dr. Upton shares how her organization is maximizing data management efficiency, such as delivering data at scale and harnessing AI to expedite R&D, and her thoughts on the challenges of setting standards. She also talks about Pistoia Alliance’s history and mi...

Going from one field to the next can be a tricky thing to navigate. In this episode of Trends from the Trenches, host Stan Gloss speaks with Tom Miller, Co-Founder and CEO of Iambic Therapeutics, about his journey from academia as a professor at the California Institute of Technology to getting B-Round funding as the CEO of his own start-up. Miller discusses why he started his company, what inspired him to turn his research into an entrepreneurial venture, and how combining physics and data can create more data-efficient AI algorithms that vastly improve accuracy in prediction models. Miller also...

In this episode of Trends from the Trenches, host Stan Gloss speaks with Heidi Rehm, PhD, Chair Elect of the Global Alliance for Genomics and Health (GA4GH), about data sharing policies and standards that can advance both genomics and health. Rehm discusses the benefits of data sharing on a global scale, how organizations can reduce friction of people’s usage and adoption of standards, and successful examples of implementation. She also shares her thoughts on the future of AI, “data citizenship,” and how the COVID-19 pandemic paved a hopeful road of new opportunities for researchers everywhere to work togeth...

In the latest episode of the Trends from the Trenches podcast, host Stan Gloss and Bryn Roberts, PhD, Global Head of Data & Analytics at Roche Information Solutions explore the Why and the How behind AI. What used to be “happily left a bit in the background” is now main stage thanks to everyone’s new interest in ChatGPT. Roberts recommends applying pharma’s Target Product Profiles (TPPs) to AI products as well: understanding what a tool or model should do, who its users are, how it will be delivered, and what biases to watch out for. This approach will help us...

After the “magical moment of hope” when the first human genome was sequenced, Jeanne Kehren switched from veterinary medicine to the pharmaceutical industry. Today, she is the SVP of Digital & Commercial Innovation and CIO at Bayer Pharmaceuticals and works in various areas, including sustainability, digital health, and digital transformation. In this episode of Trends from the Trenches, host Stan Gloss speaks with Kehren about what drew her to pharmaceuticals, the potential future of digital twins, and what innovation means to her. Kehren also shares her thoughts about generative AI’s role in innovation and the impact it might have on the...

A few years ago, artificial intelligence was in its developmental stages. Today, it is widely used by various industries and several companies are exploring new ways to utilize its tremendous potential. In this episode of Trends from the Trenches, Stan Gloss speaks with Jarrod Anderson, Senior Director of Artificial Intelligence at ADM, who discusses prioritizing projects, selecting the best team members, and overcoming the biggest challenges that companies encounter in the machine learning sphere. He also shares his thoughts on the future of AI, including its role in sustainability and environmental preservation, as well as its contributions on productivity...

In this episode of Trends from the Trenches, Stan Gloss speaks with Efosa Ojomo, director of the Global Prosperity Group at the Clayton Christensen Institute (CCI) and coauthor of The Prosperity Paradox: How Innovation Can Lift Nations Out of Poverty, about the parallels between consumption economy and life sciences research. Ojomo discusses how relying on data metrics does not necessarily provide full insight on what a consumer audience needs, why it is important to also look at non-consumers, how to overcome barriers of consumption—and how all of these questions can apply to research. He also delves into his ex...

Bryn Roberts has spent thirty years in informatics and data, most recently at Roche and before that at AstraZeneca. Now as Global Head of Data and Analytics at Roche Information Solutions, Roberts applies his career-long learnings to the current era of data in life sciences, offering advice for building data citizenship, creating a FAIR data culture, and avoiding vendor lock-in.  

Links from this episode:  
Bryn Roberts: Reflections on Pharma’s Scientific Computing Journey
Bio-IT World
BioTeam 
Roche 

Bio-IT World’s Trends from the Trenches podcast delivers your insider’s look at th...

At Pfizer, AI plays a key role in every step of the drug discovery process, Anastasia Christianson, Global Head of AI, ML, Analytics, and Data at Pfizer, tells Stan Gloss on the latest episode of the Trends from the Trenches podcast. Christianson lists the areas at Pfizer where AI is in play and for which she has AI/ML responsibility: research and discovery, clinical development, manufacturing supply chain, commercial, medical affairs, human resources, financial departments, and more. Pfizer doesn’t have a digital strategy, Christianson says, turning that buzzword on its head. “Instead, we have a business strategy for a di...

Kjiersten Fagnan is an applied mathematician enamored of biology’s messy datasets. Now, as chief informatics officer at the Department of Energy Joint Genome Institute (JGI), located at Lawrence Berkeley National Laboratory, she finds bioinformatics' computational and data challenges very different from applied math or partial differential equations. Fagnan is the newest guest on the Trends from the Trenches podcast, speaking with host Stan Gloss of BioTeam about JGI’s Genome Citation Service, a new offering that connects the broader community with the organization’s massive data resources and infrastructure. 

Fagnan talks about the centralized data management system...

The steel industry is not a common birthplace of biotech companies, but Andrew Hopkins traces the ideas that became Exscientia back to his time there. New technologies and new processes replaced nearly 90% of the steel workforce, and Hopkins kept those market lessons. He says, “When I ended up in pharma and biotech, I had a very different perception of the power of commerce and markets and what they can potentially drive, and the power of new technology to position oneself in those markets.”  

In this episode, Andrew Hopkins, CEO and Executive Director of Exscientia, speaks with host Stan...

After ten years of working on a specific disease, Chris Gibson’s graduate school lab tested their treatment theory on an animal model. It not only didn’t work, it actually made the animals worse. The experience prompted Gibson to look into how other tools and techniques could be brought to bear on biological programs. And so he quit medical school to co-found Recursion Pharmaceuticals where he is now CEO.  

In this episode, Gibson sits down with host Stan Gloss of BioTeam, about Recursion’s mission to decode biology, radically improve lives, and set big goals to innovat...

Terry Lo has been in healthcare for almost 25 years, with business and commercial roles across pharma, diagnostics, and life sciences, but his most recent role—CEO at Vizgen—connects him with what he calls, “without a doubt the most exciting space I’ve been involved with.” In this episode, Lo speaks with BioTeam’s Stan Gloss about spatial biology, why it matters, and how he imagines the technology changing healthcare’s future.  

Lo details how a science that explores the intersections between visual histology and molecular markers creates more complete images or maps of healthy and diseased tissues to bett...

Host Stan Gloss, founder of BioTeam, talks with Aaron Friedman, HealthAI Principal Product Manager at Amazon Web Services, about the launch of Amazon Omics. This new purpose-built service helps healthcare and life science organizations store, query, and analyze genomic, transcriptomic, and other omics data to generate insights that improve health and advance scientific discoveries. The platform simplifies and accelerates the process of storing and analyzing data for research and clinical applications. 

On the day of the announcement, Friedman discusses why Amazon Omics will best suit small and large biotech companies and make it easier for various organizations t...

Host Stan Gloss, founder of BioTeam, invites Mike Tarselli, chief scientific officer at TetraScience, to chat about data and how the life sciences industry thinks about our primary product. They discuss the tech sector’s influence on pharma in switching from a project mindset that yields outputs to a product mindset that yields outcomes and why the industry should use traditional supply chain mechanics as the blueprint to generate and package data. 

Tarselli also advises biotech companies experiencing a data transformation—as opposed to a digital transformation—to start small and resist the urge to make sweeping changes...

Graphene has quickly become a biotech buzzword as scientists aim to better connect with biology and usher in a new wave of technological advancements. Outperforming silicon at nearly every turn, graphene is one of the most biocompatible tools for extracting valuable information without disrupting biological systems. “Graphene is a single layer of carbon molecules. Everything in our body is made of carbon. It’s the most compatible material we can find that has amazing electronic properties. You can build electronics and conjugate with biology without impacting the biology and without biology impacting it,” says Dr. Kiana Aran, chief scientific office...

In the latest episode of Bio-IT World’s Trends from the Trenches podcast, host Stan Gloss, founder of BioTeam, talks with Fernanda Foertter, director of developer relations at Voltron Data, about her AI experiences in the past few years, whether we’ve made any real progress, and if she thinks AI is a pipe dream. “It feels like it’s a pipe dream to be able to get these things right [today]... I think as we get the ability to regularize and get data in a way that looks as harmonized as possible, things will improve. But the problem is getti...

Victoria Gamerman’s love of analytics and math came from her grandmother—the first mathematician she knew. And in her nearly decade at Boehringer Ingelheim, she’s been putting that love to use as the Global Head of Data Governance and Insights.  In the latest episode of Bio-IT World’s Trends from the Trenches podcast, host Stan Gloss, founder of BioTeam, talks with Gamerman about real world data, why it’s important for drug discovery, and the shifts happening around how we think about data. “Historically what I have seen and observed in terms of industry trends and trends from regulato...

Neurodiversity is inconvenient in a classroom; George Church knows firsthand. But in the latest episode of Bio-IT World’s Trends from the Trenches podcast, Church tells host, Stan Gloss: “I’m interested in overcoming the inconvenience of having people who are a little bit out on the bell curve… You don’t want necessarily to train everybody in your lab to be as close to the ideal citizen as possible. You just want them to be comfortable enough that they can deal with their diversity.”   

Church goes on to talk about how neurodiversity shaped his education and scientific car...

Susan Gregurick, Associate Director for Data Science and Director of the Office of Data Science Strategy at the National Institutes of Health (NIH), speaks with Stan Gloss, podcast host and BioTeam founder, about the next iteration of the NIH Strategic Plan for Data Science and the lessons learned from the recent pandemic. “COVID just told us how much we weren’t doing, and how challenging it is to really get FAIR data into the hands of researchers in a timely fashion so they can find it, access it, and use it. We are nowhere close to actually accomplishing that goal...

Dr. Kim Branson’s intense interest in drug discovery and structural biology quickly led to an interest in machine learning. After receiving multiple degrees from esteemed universities in Australia, Branson trained at Stanford and now works as the Senior Vice President and Global Head of AI/ML at GSK. With host, Stan Gloss, Branson shares his work in creating “biological twins.” These 3-D tumor culture models replicate cancer and their respective immune environments. Branson and his team monitor tumor and immune responses to cancer drugs in real-time. The clinical implications of anticipating a tumor’s every move within a patient’...